Insider Buying: PureTech Health (LON:PRTC) Insider Buys £939.44 in Stock

PureTech Health plc (LON:PRTC) insider Michele Holcomb purchased 93,944 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were purchased at an average cost of GBX 1 per share, with a total value of £939.44.

Michele Holcomb also recently made the following trade(s):

• On Wednesday, July 8th, Michele Holcomb acquired 31,481 shares of PureTech Health stock. The stock was purchased at an average price of GBX 119 per share, for a total transaction of £37,462.39.

PureTech Health Price Performance

PRTC stock opened at GBX 119.12 on Monday. The stock has a market capitalization of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79. The firm’s 50-day moving average price is GBX 127.34 and its two-hundred day moving average price is GBX 126.62. The company has a current ratio of 6.59, a quick ratio of 2.51 and a debt-to-equity ratio of 6.33. PureTech Health plc has a 12-month low of GBX 104.71 and a 12-month high of GBX 146.40.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reiterated a “buy” rating and issued a GBX 508 price objective on shares of PureTech Health in a research report on Monday, July 13th. One analyst has rated the stock with a Buy rating, According to MarketBeat, PureTech Health currently has a consensus rating of “Buy” and a consensus target price of GBX 508.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.